Skip to main content

In Brief This Week: NanoString, OpGen, Genfit, and More

NEW YORK (360Dx) – NanoString said this week that it closed its previously announced underwritten public offering of 5.2 million shares of its common stock at $23 per share. The firm sold nearly 3.2 million shares of common stock, and the underwriters exercised their option in full to purchase an additional 675,000 shares of common stock. NanoString stockholder Clarus Lifesciences II also sold 2 million shares of common stock. JP Morgan, UBS Investment Bank, and Cowen were joint book-running managers for the offering and Baird was the lead manager. 

NanoString's net proceeds were approximately $68.3 million, and the company said it intends to use the money for working capital and general corporate purposes.

Separately, the firm said this week that a sales agreement between itself and investment bank Cowen has been mutually terminated. The agreement, which originated in January 2018, provided that NanoString could sell its common stock for up to $40 million in aggregate sales proceeds, through an at-the-market equity offering program, with Cowen as sales agent. No shares were sold under the now-terminated agreement.


OpGen this week closed a previously announced underwritten public offering of 9 million shares of its common stock at a public offering price of $.60 per share. All of the shares were sold by OpGen. The aggregate gross proceeds to the company were approximately $5.4 million. OpGen said it plans to use the proceeds of the offering to support the anticipated US Food and Drug Administration 510(k) submission of its Acuitas AMR Gene Panel test.


Genfit said that it has closed its previously announced public offering of about 7.6 million ordinary shares and raised gross proceeds of about $155.4 million.

The offering consisted of about 7.1 million ordinary shares in the form of American Depositary Shares, each representing one ordinary share, at a public price of $20.32 per ADS. A concurrent private placement of 500,000 ordinary shares in Europe and countries outside the US was also made at €18 per ordinary share.

The number of shares issued in the ADS offering included an additional 997,500 ADSs issued to the offering's underwriters who exercised their option to purchase additional shares.


American Esoteric Laboratories said this week that it has been designated a Blue Cross and Blue Shield of Alabama Preferred Plus Network laboratory for Alabama. AEL said it is one of three laboratory service providers that have been designated as a preferred lab with BCBSAL, resulting in coverage to more than 1.5 million people in that state. AEL, a division of Sonic Healthcare, provides laboratory services in the Mid-South region of the US as well as Alabama, including a network of local services.


Oxford Immunotec this week announced a production initiative to bring the benefits of the T-Spot.TB test to the Russian Federation.

The firm said that it has been working with a local distribution partner, PharmLine, and has seen expanding uptake of the test since the T-Spot.TB test received approval in the Russian Federation in 2013.

In collaboration with PharmLine, Oxford Immunotec will now also work with Generium Joint Stock, which will manufacture the test at its factory in the Vladimir region of the Russian Federation.

This is expected to reduce the cost of the test for patients and expand access to it in the Russian Federation, Oxford Immunotec said. Further, Generium will work with PharmLine on marketing and distribution of the test and apply for national TB control tenders.


Caris Life Sciences announced this week that Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine has become the 26th cancer center to join the Precision Oncology Alliance, a collaborative network of cancer centers that is developing standards of care and best practices for the application of tumor molecular profiling. Through the Precision Oncology Alliance, the Sylvester Comprehensive Cancer Center will collect molecular data and longitudinally track outcomes data for patients who have their tumors profiled with the Caris Molecular Intelligence platform. In addition, researchers from the center will be able to contribute to and publish data, and participate in clinical trials collaborations to validate Next Generation Profiling (NGP), Caris' proprietary machine learning algorithms to improve patient diagnosis and treatment selection.  


In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.